New drug cocktail aims to shrink breast tumors before surgery
NCT ID NCT07189884
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study is testing whether combining two targeted drugs (pyrotinib and dalpiciclib) with standard hormone therapy can shrink tumors in people with HR+HER2 low breast cancer before they have surgery. The study plans to enroll 33 patients with locally advanced disease. The main goal is to see how many patients have their tumors shrink or disappear completely after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pyrotinib and Dalpiciclib tablets combined with standard hormone therapy
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for HR+HER2 low breast cancer, potentially increasing the chance of eliminating all cancer cells before surgery.
What could go wrong
This is a very early, small study (33 people) with no control group, so results may not be conclusive. Side effects from the drug combination are possible and not yet fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER (LABC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••